PPIPT01886
Target Protein Information
| Protein_Name | Mu-type opioid receptor |
|---|---|
| Protein_Sequence | MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP |
| Organism_Source | Homo sapiens |
| Functional_Classification | GPCR (u-opioid receptor) |
| Cellular_Localization | Plasma membrane |
| Gene_Names | OPRM1 |
| UniProt_ID | P35372 |
| Protein-Protein Interaction Networks | |
Peptide Basic Information
| Peptide_Name | EU-A102 |
|---|---|
| Peptide_Sequence | XXXK |
| Peptide_Length | 4 |
| Peptide_SMILES | NCCCC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)O |
| Chemical_Modification | X1=2,6-dimethyltyrosine; X2=1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; K4-N钄=1閳-octyl-u-D-glucuronyl |
| Cyclization_Method | None |
| Linear/Cyclic | Cyclic |
| N-terminal_Modification | Free |
| C-terminal_Modification | Amide |
| Amino_Acid_Distribution | |
|
|
|
Peptide Physicochemical
| Molecular_Weight | 317.35 |
|---|---|
| Aliphatic_Index | 0.00000 |
| Aromaticity | 0.00000 |
| Average_Rotatable_Bonds | 2.75000 |
| Charge_at_pH_7 | 0.99769 |
| Isoelectric_point | 9.70000 |
|---|---|
| Number_of_Hydrogen_Bond_Acceptors | 6 |
| Number_of_Hydrogen_Bond_Donors | 6 |
| Topological_Polar_Surface_Area | 176.64000 |
| X_logP_energy | -3.12410 |
Interaction Information
| Affinity | KD=60 nM |
|---|---|
| Affinity_Assay | cAMP accumulation assay |
| PDB_ID | None |
| Type | Agonist |
| Structure | |
Reference Information
| Document_Type | Patent |
|---|---|
| Title | IMPROVED PEPTIDE PHARMACEUTICALS |
| Release_Year | 2019 |
| Patent_ID | EP3566711A1 |